Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model

Low‐dose methotrexate (MTX) is a first‐line therapy for the treatment of arthritis. However, there is considerable interindividual variability in MTX exposure following standard dosing. Polymorphisms in SLCO1B1 significantly effect MTX clearance, altering therapeutic response. One decreased function...

Descripción completa

Detalles Bibliográficos
Autores principales: Taylor, Zachary L., Thompson, Lauren E., Bear, Heather, Mizuno, Tomoyuki, Vinks, Alexander A., Ramsey, Laura B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604247/
https://www.ncbi.nlm.nih.gov/pubmed/34121338
http://dx.doi.org/10.1111/cts.13086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604247/
https://www.ncbi.nlm.nih.gov/pubmed/34121338
http://dx.doi.org/10.1111/cts.13086

Ejemplares similares